OverviewStudy detailsEligibilityThings to knowResearchStudy plan
info
Simplify with AI

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

PHASE3ACTIVE_NOT_RECRUITING

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.

Study details:

The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before randomization
  2. Has moderately to severely active UC
  3. Weight ≥40 kg
  4. Satisfies at least 1 of the following criteria:
  5. Has had an inadequate response or loss of response to 1 or more protocol-specified UC treatments
  6. Protocol specified corticosteroid dependence
  7. Has been intolerant to 1 or more protocol-specified UC treatments
  8. Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable
  9. Adolescent participants ≥16 and <18 years of age can participate if approved by the country or regulatory/health authority
  10. A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding and Is not a participant of childbearing potential (POCBP); or is a POCBP and uses an acceptable contraceptive method, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention, medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy

Exclusion criteria

  1. Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment.
  2. Has a current diagnosis of fulminant colitis and/or toxic megacolon
  3. Has UC limited to the rectum (i.e, must have evidence of UC extending beyond the rectosigmoid junction, which is ~10 cm from the anal margin)
  4. Has a current or impending need for colostomy or ileostomy
  5. Has had a total proctocolectomy or partial colectomy
  6. Has received fecal microbial transplantation within 4 weeks before randomization
  7. Has had UC exacerbation requiring hospitalization within 2 weeks before screening
  8. Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed
  9. Has any active or serious infections without resolution after adequate treatment
  10. Has had cytomegalovirus infection that resolved less than 4 weeks before screening
  11. Has a transplanted organ which requires continued immunosuppression
  12. Has a history of cancer (except fully treated non-melanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years
  13. Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
  14. Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidelines), or inadequately treated TB (for participants with history of TB)
  15. Has confirmed or suspected COVID-19
  16. Has a history of drug or alcohol abuse within 6 months prior to screening
  17. Has had major surgery within 3 months before screening or has a major surgery planned during the study
  18. Is currently receiving or is planning to receive total parenteral nutrition at any time during study treatment
  19. Has received UC-related antibiotics and has not been on stable doses for at least 14 days before randomization or has discontinued these medications within 14 days of randomization
  20. Requires treatment with a therapy that does not adhere to the protocol-specified guidance parameters
  21. Has received protocol-specified prohibited medications
  22. Has had prior exposure to tulisokibart or another anti-tumor necrosis factor-like cytokine 1A (TL1A) antibody

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    PHASE3

trial

Study ID

NCT06052059

Intervention or treatment

DRUG: IV Tulisokibart

DRUG: IV Placebo

DRUG: SC Tulisokibart

DRUG: SC Placebo

Conditions

  • Ulcerative Colitis

  • Condition: Ulcerative Colitis

  • DRUG: IV Tulisokibart and other drugs

  • Kingswood, New South Wales, Australia and more

  • Sponsor: Merck Sharp & Dohme LLC

Save

Share

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Nepean Hospital-Gastroenterology/Hepatology ( Site 2501)

Select from list below to view details:

  • Nepean Hospital-Gastroenterology/Hepatology ( Site 2501)

    Kingswood, New South Wales, Australia

  • Concord Repatriation General Hospital-Gastroenterology and Liver Services ( Site 2508)

    Sydney, New South Wales, Australia

  • Royal Brisbane and Women's Hospital ( Site 2500)

    Brisbane, Queensland, Australia

  • Mater Misericordiae Limited-Gastroenterology ( Site 2506)

    Brisbane, Queensland, Australia

Loading map...

Who is running the clinical trial?

MS&DL

Merck Sharp & Dohme LLC

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Study 1: High Dose Induction, High Dose Maintenance
  • Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen.
Drug: IV Tulisokibart, Drug: SC Tulisokibart
    EXPERIMENTAL: Study 1: High Dose Induction, Low Dose Maintenance
    • Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
    Drug: IV Tulisokibart, Drug: SC Tulisokibart, Drug: SC Placebo
      EXPERIMENTAL: Study 1: Low Dose Induction, Low Dose Maintenance
      • Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen.
      Drug: IV Tulisokibart, Drug: SC Tulisokibart, Drug: SC Placebo
        PLACEBO_COMPARATOR: Study 1: Placebo
        • Participants receive IV placebo, followed by an SC placebo regimen.
        Drug: IV Tulisokibart, Drug: IV Placebo, Drug: SC Placebo
          EXPERIMENTAL: Study 1: High Dose Extension
          • Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
          Drug: SC Tulisokibart
            EXPERIMENTAL: Study 1: Low Dose Extension
            • Participants receive a low dose SC tulisokibart and placebo regimen. Participants may be enrolled in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites.
            Drug: SC Tulisokibart, Drug: SC Placebo
              EXPERIMENTAL: Study 2: High Dose Induction
              • Participants receive high dose IV tulisokibart.
              Drug: IV Tulisokibart
                EXPERIMENTAL: Study 2: Low Dose Induction
                • Participants receive low dose IV tulisokibart.
                Drug: IV Tulisokibart
                  PLACEBO_COMPARATOR: Study 2: Placebo
                  • Participants receive IV placebo.
                  Drug: IV Tulisokibart, Drug: IV Placebo, Drug: SC Placebo
                    EXPERIMENTAL: Study 2: High Dose Extension
                    • Participants receive a high dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
                    Drug: SC Tulisokibart
                      EXPERIMENTAL: Study 2: Low Dose Extension
                      • Participants receive a low dose SC tulisokibart regimen. Participants may be enrolled in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
                      Drug: SC Tulisokibart, Drug: SC Placebo

                        What is the study measuring?

                        Primary Outcome

                        MeasureDescriptionTime Frame
                        Study 1: Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12The Modified Mayo Score (MMS) is a composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.Week 12
                        Study 1: Percentage of Participants Achieving Clinical Remission Per MMS at Week 52The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.Week 52
                        Study 2: Percentage of Participants Achieving Clinical Remission Per MMS at Week 12The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.Week 12

                        Secondary Outcome

                        MeasureDescriptionTime Frame
                        Study 1: Percentage of Participants With One or More Adverse Events (AEs)An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE will be reported.Up to approximately 52 weeks
                        Study 1: Percentage of Participants Who Discontinued Study Intervention Due to an AEAn AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.Up to approximately 52 weeks
                        Study 1: Percentage of Participants Achieving Clinical Response Per Partial Modified Mayo Score (pMMS) at Week 2The partial Modified Mayo Score (pMMS) is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as pMMS reduction of 1 or more points and 30% or more, plus a reduction of 1 or more points in RBS or an absolute RBS of 0 or 1.Week 2
                        Study 1: Percentage of Participants With Endoscopic Improvement at Week 12Endoscopic improvement is defined as Mayo endoscopic subscore (ES) of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 12
                        Study 1: Percentage of Participants Achieving a Clinical Response Per MMS at Week 12The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as an MMS reduction of 2 or more points and 30% or more, plus a reduction of more than 1 point in RBS or an absolute RBS of 0 or 1.Week 12
                        Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement (HEMI) at Week 12HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).Week 12
                        Study 1: Percentage of Participants Achieving Clinical Remission Per pMMS at Week 12pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical remission per pMMS is defined as an RBS of 0 and SFS of ≤1.Week 12
                        Study 1: Percentage of Participants With Endoscopic Remission at Week 12ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration). Endoscopic remission is defined as an ES of 0.Week 12
                        Study 1: Percentage of Participants Reporting No Bowel Urgency at Week 12Bowel urgency is measured using an NRS, which rates bowel urgency on a 0-11 scale of increasing severity. Resolution is defined as a score of 0 or 1 in participants who had a baseline score of 3 or more.Week 12
                        Study 1: Percentage of Participants Reporting No Abdominal Pain at Week 12Abdominal pain is measured on a 0-4 NRS of increasing pain severity. Absence of abdominal pain is defined as a rating of 0.Week 12
                        Study 1: Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 12The IBDQ measures health related quality of life in subjects with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges from 32 to 224. IBDQ remission is defined as a score of at least 170.Week 12
                        Study 1: Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0-52 point scale, with greater scores indicating a better fatigue-related quality of life. The change from baseline in FACIT-Fatigue score will be presented.Baseline and Week 12
                        Percentage of Diagnostic Assay Positive (Dx+) Participants Achieving Clinical Remission Per MMS at Week 12Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.Week 12
                        Percentage of Dx+ Participants With Endoscopic Improvement at Week 12Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. Endoscopic improvement is defined as ES of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 12
                        Study 1: Percentage of Participants Achieving Histologic-Endoscopic Remission (HER) at Week 12HER is defined as a Geboes score of less than 2 and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).Week 12
                        Study 1: Percentage of Participants with Endoscopic Improvement at Week 52Endoscopic improvement is defined as ES of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 52
                        Study 1: Percentage of Participants Achieving Corticosteroid-Free Clinical Remission Per MMS at Week 52The Modified Mayo Score (MMS) is a composite score of ulcerative colitis (UC) disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Corticosteroid-free clinical remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS, and no corticosteroid use for ≥90 days before Week 52.Week 52
                        Study 1: Percentage of Participants Achieving HEMI at Week 52HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).Week 52
                        Study 1: Percentage of Participants Achieving Clinical Remission Per pMMS at Week 52pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical remission per pMMS is defined as an RBS of 0 and SFS of ≤1.Week 52
                        Study 1: Percentage of Participants Achieving Sustained Clinical Remission Per MMS at Both Week 12 and Week 52The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Sustained clinical remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS, at both Week 12 and Week 52.Week 12 and Week 52
                        Study 1: Percentage of Participants Reporting No Bowel Urgency at Week 52Bowel urgency is measured using an NRS, which rates bowel urgency on a 0-11 scale of increasing severity. Resolution is defined as a score of 0 or 1 in participants who had a baseline score of 3 or more.Week 52
                        Study 1: Percentage of Participants Reporting No Abdominal Pain at Week 52Abdominal pain is measured on a 0-4 NRS of increasing pain severity. Absence of abdominal pain is defined as a rating of 0.Week 52
                        Study 1: Percentage of Participants With Endoscopic Remission at Week 52ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration). Endoscopic remission is defined as an ES of 0.Week 52
                        Study 1: Percentage of Participants with Sustained Endoscopic Improvement at Both Week 12 and Week 52Sustained endoscopic improvement is defined as an ES of 0 or 1 at both Week 12 and Week 52. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 12 and Week 52
                        Study 1: Percentage of Participants Achieving HER at Week 52HER is defined as a Geboes score of less than 2 and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).Week 52
                        Study 1: Percentage of Participants Achieving IBDQ Remission at Week 52The IBDQ measures health related quality of life in subjects with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges from 32 to 224. IBDQ remission is defined as a score of at least 170.Week 52
                        Study 1: Change from Baseline in FACIT-Fatigue Score at Week 52The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0-52 point scale, with greater scores indicating a better fatigue-related quality of life. The change from baseline in FACIT-Fatigue score will be presented.Baseline and Week 52
                        Study 1: Percentage of Dx+ Participants Achieving Clinical Remission Per MMS at Week 52Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.Week 52
                        Study 1: Percentage of Dx+ Participants With Endoscopic Improvement at Week 52Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. Endoscopic improvement is defined as ES of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 52
                        Study 2: Percentage of Participants With One or More AEsAn AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experience an AE will be reported.Up to approximately 12 weeks
                        Study 2: Percentage of Participants Who Discontinued Study Intervention Due to an AEAn AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.Up to approximately 12 weeks
                        Study 2: Percentage of Participants with Clinical Response Per pMMS at Week 2pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as pMMS reduction of 1 or more points and 30% or more, plus a reduction of 1 or more points in RBS or an absolute RBS of 0 or 1.Week 2
                        Study 2: Percentage of Participants With Endoscopic Improvement at Week 12Endoscopic improvement is defined as Mayo endoscopic subscore (ES) of 0 or 1. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.Week 12
                        Study 2: Percentage of Participants Achieving a Clinical Response Per MMS at Week 12The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as an MMS reduction of 2 or more points and 30% or more, plus a reduction of more than 1 point in RBS or an absolute RBS of 0 or 1.Week 12
                        Study 2: Percentage of Participants Achieving HEMI at Week 12HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).Week 12
                        Study 2: Percentage of Participants Achieving Clinical Remission Per pMMS at Week 12pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical remission per pMMS is defined as an RBS of 0 and SFS of ≤1.Week 12
                        Study 2: Percentage of Participants With Endoscopic Remission at Week 12ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration). Endoscopic remission is defined as an ES of 0.Week 12
                        Study 2: Percentage of Participants Reporting No Bowel Urgency at Week 12Bowel urgency is measured using a numeric rating scale (NRS), which rates bowel urgency on a 0-11 scale of increasing severity.Week 12
                        Study 2: Percentage of Participants Reporting No Abdominal Pain at Week 12Abdominal pain is measured on a 0-4 NRS of increasing pain severity. Absence of abdominal pain is defined as a rating of 0.Week 12
                        Study 2: Percentage of Participants Achieving IBDQ Remission at Week 12The IBDQ measures health related quality of life in subjects with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges from 32 to 224. IBDQ remission is defined as a score of at least 170.Week 12
                        Study 2: Change from Baseline in FACIT-Fatigue Score at Week 12The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0-52 point scale, with greater scores indicating a better fatigue-related quality of life. The change from baseline in FACIT-Fatigue score will be presented.Baseline and Week 12
                        Study 2: Percentage of Participants Achieving HER at Week 12HER is defined as a Geboes score of less than 2 and ES of 0 or 1. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation.Week 12
                        Are you running this trial?If you're a clinic or sponsor, you can claim this study.
                        Claim this trial

                        References

                        Clinical Trials Gov: A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

                        Other trials to consider

                        Loading suggested trials...

                        Top searched conditions

                        Breast CancerLung CancerType 2 DiabetesDermatitisAlzheimersParkinsonsLupusCrohn’s DiseaseAsthmaHypertensionCOPDMultiple SclerosisOsteoarthritisHIV/AIDSPsoriasisStrokeObesityProstate CancerDepressionCardiovascular